Michael Rink

List of Publications by Year
in descending order

174 papers	5,084 citations	117619 34 h-index	114455 63 g-index
178 all docs	178 docs citations	178 times ranked	4741 citing authors

#	Article	IF	Citations
1	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. Journal of Urology, 2013, 189, 1214-1221.	0.4	291
2	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 379-387.	2.2	260
3	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 65, 210-217.	1.9	201
4	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	1.9	163
5	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. European Urology, 2014, 65, 742-754.	1.9	159
6	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. European Journal of Cancer, 2013, 49, 1889-1897.	2.8	154
7	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. European Urology, 2012, 61, 854-855.	1.9	152
8	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
9	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	2.5	128
10	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.4	114
11	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Nonâ€"muscle-invasive Bladder Cancer. European Urology, 2013, 63, 724-732.	1.9	105
12	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. European Urology, 2013, 64, 456-464.	1.9	101
13	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyondâ€"A Comprehensive Review of the Current Literature. Journal of Urology, 2016, 195, 254-263.	0.4	99
14	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	1.9	98
15	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	1.9	93
16	Detection of circulating tumour cells in peripheral blood of patients with advanced nonâ€metastatic bladder cancer. BJU International, 2011, 107, 1668-1675.	2.5	89
17	Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. European Urology, 2020, 77, 55-65.	1.9	85
18	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European Urology Focus, 2015, 1, 17-27.	3.1	80

#	Article	IF	Citations
19	Predictors of cancerâ€specific mortality after disease recurrence following radical cystectomy. BJU International, 2013, 111, E30-6.	2.5	77
20	Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World Journal of Urology, 2020, 38, 1165-1175.	2.2	72
21	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis, 2009, 101, 1147-1155.	3.4	67
22	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. European Urology, 2013, 64, 837-845.	1.9	61
23	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urologyâ€“Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. BJU International, 2018, 121, 252-259.	2.5	61
24	Pathogen-induced tissue-resident memory T _H 17 (T _{RM} 17) cells amplify autoimmune kidney disease. Science Immunology, 2020, 5, .	11.9	58
25	Prognostic significance of markers of systemic inflammatory response in patients with nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 483.e17-483.e24.	1.6	54
26	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Annals of Surgical Oncology, 2012, 19, 4337-4344.	1.5	53
27	Differences in trends in the use of robotâ€assisted and open radical cystectomy and changes over time in periâ€operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. BJU International, 2019, 124, 656-664.	2.5	53
28	Female with bladder cancer: what and why is there a difference?. Translational Andrology and Urology, 2016, 5, 668-682.	1.4	52
29	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. Current Urology Reports, 2012, 13, 122-135.	2.2	51
30	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World Journal of Urology, 2016, 34, 97-103.	2.2	51
31	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	1.9	50
32	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2014, 191, 316-322.	0.4	49
33	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e1-21.e9.	1.6	48
34	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Nonâ€“muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	3.1	48
35	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. European Urology Focus, 2016, 2, 79-85.	3.1	39
36	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	2.2	37

#	Article	IF	Citations
37	Current Disease Management of Primary Urethral Carcinoma. European Urology Focus, 2019, 5, 722-734.	3.1	34
38	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). OncoImmunology, 2020, 9, 1738798.	4.6	34
39	A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. International Journal of Cancer, 2017, 140, 381-389.	5.1	33
40	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	6.8	33
41	Genderâ€specific effect of smoking on upper tract urothelial carcinoma outcomes. BJU International, 2013, 112, 623-637.	2.5	31
42	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 433-440.	1.6	31
43	Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity. European Urology, 2018, 73, 910-922.	1.9	31
44	Psychometric validation of a German language version of a PROM for urethral stricture surgery and preliminary testing of supplementary ED and UI constructs. World Journal of Urology, 2016, 34, 369-375.	2.2	30
45	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World Journal of Urology, 2017, 35, 1401-1407.	2.2	29
46	Histopathological Characteristics of Buccal Mucosa Transplants in Humans after Engraftment to the Urethra: A Prospective Study. Journal of Urology, 2014, 192, 1725-1729.	0.4	28
47	Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World Journal of Urology, 2015, 33, 1753-1761.	2.2	28
48	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU International, 2017, 119, 854-861.	2.5	27
49	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU International, 2013, 111, 74-84.	2.5	26
50	The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Urology, 2015, 86, 92-98.	1.0	26
51	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. Journal of Urology, 2015, 194, 1456-1462.	0.4	25
52	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget, 2017, 8, 56398-56407.	1.8	25
53	Prognostic value of modified Glasgow Prognostic Score in nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e19-179.e28.	1.6	25
54	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis, 2009, 101, 1147-55.	3.4	25

#	Article	IF	Citations
55	Î² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Human Pathology, 2017, 61, 210-220.	2.0	23
56	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e1-233.e6.	1.6	22
57	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	2.2	22
58	The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Translational Andrology and Urology, 2017, 6, 1090-1110.	1.4	22
59	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	2.2	22
60	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	1.9	21
61	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2021, 39, 1757-1768.	2.2	20
62	Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. Journal of Endourology, 2021, 35, 639-646.	2.1	20
63	Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy. European Journal of Cancer, 2014, 50, 2583-2591.	2.8	19
64	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World Journal of Urology, 2015, 33, 1419-1428.	2.2	19
65	Prognostic Value of Serum Cholinesterase in Nonâ€“muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e1123-e1132.	1.9	19
66	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 580-593.	5.4	19
67	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget, 2020, 11, 237-249.	1.8	19
68	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. World Journal of Urology, 2018, 36, 1067-1072.	2.2	18
69	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Nodeâ€“Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18
70	The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World Journal of Urology, 2019, 37, 1785-1799.	2.2	18
71	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus, 2020, 6, 1226-1232.	3.1	18
72	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	2.2	18

#	Article	IF	Citations
73	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e19-531.e25.	1.6	17
74	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	2.2	16
75	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multiâ€institutional study. BJU International, 2017, 119, 234-238.	2.5	16
76	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	2.5	16
77	Older patients suffer from adverse histopathological features after radical cystectomy. International Journal of Urology, 2011, 18, 576-584.	1.0	15
78	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1716-1724.	1.6	15
79	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	1.6	15
80	Outcome of buccal mucosa graft urethroplasty: a detailed analysis of success, morbidity and quality of life in a contemporary patient cohort at a referral center. BMC Urology, 2019, 19, 18.	1.4	15
81	Î²III-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	2.2	14
82	Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy?. Current Urology Reports, 2015, 16, 46.	2.2	14
83	Prognostic value of Caveolinâ€1 in patients treated with radical prostatectomy: a multicentric validation study. BJU International, 2016, 118, 243-249.	2.5	14
84	Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 96-104.	1.9	14
85	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e1039-e1045.	1.9	14
86	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. Surgical Oncology, 2019, 28, 208-213.	1.6	14
87	Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. European Urology Focus, 2022, 8, 457-464.	3.1	14
88	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. International Urology and Nephrology, 2013, 45, 1561-1567.	1.4	13
89	The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World Journal of Urology, 2015, 33, 1769-1776.	2.2	13
90	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	2.4	13

#	Article	IF	Citations
91	Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)â€"Impact on sexual function and evaluation of patient bother using validated questionnaires. Andrology, 2020, 8, 1779-1786.	3.5	13
92	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	2.2	13
93	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	1.7	13
94	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017, 3, 161-169.	0.4	12
95	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 10.e7-10.e14.	1.6	12
96	Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?. Journal of Clinical Medicine, 2019, 8, 1459.	2.4	12
97	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	1.9	12
98	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. Translational Andrology and Urology, 2017, 6, 1018-1026.	1.4	12
99	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. Canadian Urological Association Journal, 2014, 8, 75.	0.6	11
100	The current role of circulating biomarkers in non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 61-75.	1.4	11
101	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 739.e9-739.e15.	1.6	11
102	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	2.2	11
103	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	1.4	11
104	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2016, 34, 1411-1419.	2.2	10
105	Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronieâ€™s Disease. Journal of Clinical Medicine, 2019, 8, 1121.	2.4	10
106	Pathomics in urology. Current Opinion in Urology, 2020, 30, 823-831.	1.8	10
107	Prevalence of APC and PTEN Alterations in Urachal Cancer. Pathology and Oncology Research, 2020, 26, 2773-2781.	1.9	10
108	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1687-1695.	3.1	10

#	Article	IF	Citations
109	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	1.6	9
110	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	2.2	9
111	Liquid biopsies in bladder cancerâ€"did we find the Holy Grail for biomarker analyses?. Translational Andrology and Urology, 2016, 5, 980-983.	1.4	8
112	Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 432.e1-432.e8.	1.6	8
113	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e1-179.e7.	1.6	8
114	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 43.e13-43.e20.	1.6	8
115	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	1.6	8
116	Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. Current Opinion in Urology, 2021, 31, 291-296.	1.8	8
117	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	2.5	8
118	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	1.6	8
119	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Surgical Oncology, 2020, 34, 312-317.	1.6	7
120	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World Journal of Urology, 2021, 39, 1947-1953.	2.2	7
121	Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). Frontiers in Oncology, 2021, 11, 759362.	2.8	7
122	Immunotherapy for metastatic urothelial carcinoma. Current Opinion in Urology, 2018, 28, 1-7.	1.8	6
123	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer â€“ examining the utility of classifying Ta bladder cancer based on size. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 851.e19-851.e25.	1.6	6
124	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. European Urology Open Science, 2020, 22, 45-50.	0.4	6
125	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Scientific Reports, 2020, 10, 21562.	3.3	6
126	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World Journal of Urology, 2021, 39, 2977-2985.	2.2	6

#	Article	IF	Citations
127	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	4.2	6
128	A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis. Journal of Urology, 2021, 205, 1275-1285.	0.4	6
129	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	2.7	6
130	Urinary Diversion With or Without Concomitant Cystectomy for Benign Conditions: A Comparative Morbidity Assessment According to the Updated European Association of Urology Guidelines on Reporting and Grading of Complications. European Urology Focus, 2022, 8, 1831-1839.	3.1	6
131	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.4	5
132	The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy. Journal of Clinical Medicine, 2020, 9, 3478.	2.4	5
133	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.4	5
134	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology â€“ Young Academic Urologists. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e27-195.e35.	1.6	5
135	Re: Global Effects of Smoking, of Quitting, and of Taxing Tobacco. European Urology, 2014, 66, 176-178.	1.9	4
136	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	2.2	4
137	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	1.6	4
138	The landscape of genetics and biomarkers in bladder cancer. Translational Andrology and Urology, 2017, 6, 1027-1030.	1.4	4
139	Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation. Urologia Internationalis, 2018, 101, 285-292.	1.3	4
140	Conditional analyses of recurrence and progression in patients with TaG1 nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e19-238.e27.	1.6	3
141	Learning benefits of live surgery and semi-live surgery in urologyâ€”informing the debate with results from the International Meeting of Reconstructive Urology (IMORU) VIII. World Journal of Urology, 2020, 39, 2801-2807.	2.2	3
142	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2020, 18, 128.	1.9	3
143	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e1-605.e8.	1.6	3
144	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	2.2	3

#	Article	IF	Citations
145	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	1.4	3
146	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. Future Oncology, 2021, 17, 2325-2338.	2.4	3
147	Longitudinal Evaluation of Perineogenital Pain and Postoperative Complications After One-stage Buccal Mucosal Graft Urethroplasty: A Secondary Analysis of a Randomized Controlled Trial. European Urology Focus, 2020, 7, 1157-1165.	3.1	3
148	Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. Frontiers in Surgery, 2021, 8, 763271.	1.4	3
149	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. World Journal of Urology, 2022, 40, 1489-1496.	2.2	3
150	Online tools for patient counseling in bladder and kidney cancerâ€"ready for prime time?. Translational Andrology and Urology, 2017, 6, 1123-1131.	1.4	2
151	Reply to Liang Sun and Yi Fengâ€™s Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2019;77:55â€"65. European Urology, 2020, 77, e12-e13.	1.9	2
152	Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients. Urologia Internationalis, 2023, 107, 336-343.	1.3	2
153	Why is the principle of â€œas much radicality as needed, as much organ preservation as possibleâ€•only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?. Translational Andrology and Urology, 2020, 9, 1901-1903.	1.4	2
154	Fighting the â€˜tobacco epidemicâ€™ â€“ A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 793-796.	1.6	2
155	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	1.6	2
156	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	1.0	2
157	The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 671.e17-671.e23.	1.6	1
158	Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges. Clinical Genitourinary Cancer, 2019, 17, e522-e525.	1.9	1
159	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
160	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. Journal of Clinical Oncology, 2015, 33, 4568-4568.	1.6	1
161	Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.. Journal of Clinical Oncology, 2018, 36, 495-495.	1.6	1
162	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. Journal of Clinical Oncology, 2014, 32, 4587-4587.	1.6	1

#	Article	IF	Citations
163	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: Analysis of the STAR TOR registry.. Journal of Clinical Oncology, 2020, 38, 628-628.	1.6	1
164	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	3.7	1
165	Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinomaâ€"Data from a Prospective, Multicenter Experience. European Urology, 2016, 69, 373-374.	1.9	0
166	Editorial Comment. Journal of Urology, 2017, 197, 558-558.	0.4	0
167	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchiâ€™s Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55â€"65. European Urology, 2020, 78, e77-e78.	1.9	0
168	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly â€"An International Multicenter Study. Bladder Cancer, 2021, 7, 173-185.	0.4	0
169	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2012, 30, 281-281.	1.6	0
170	Electronic cigarettes and bladder cancer â€" a game-changer?. Nature Reviews Urology, 2020, 17, 435-436.	3.8	0
171	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. Journal of Clinical Oncology, 2020, 38, TPS770-TPS770.	1.6	0
172	Effect of comorbidities/comedications on treatment outcomes with sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Subgroup analyses from the STAR-TOR registry.. Journal of Clinical Oncology, 2020, 38, 631-631.	1.6	0
173	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. Acta OncolÃ³gica, 2022, 61, 52-57.	1.8	0
174	Re: Christopher Soliman, Niranjan J. Sathianathen, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.022. European Urology, 2022, 81, e150-e150.	1.9	0